Five patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2035
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2041.
US 10,745,717
Vectors and Methods for Targeted Integration in Loci Comprising Constitutively Expressed Genes
Nov 10, 2035
US 12,394,224
Detecting Cells of Interest in Large Image Datasets Using Artificial Intelligence
Feb 20, 2040
US 11,989,960
Detecting Cells of Interest in Large Image Datasets Using Artificial Intelligence
Feb 25, 2041
202420282032203620402041
27 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2041 · High confidence
Also notable
Ends Nov 2035 · High confidence
Also notable
Ends Feb 2040 · High confidence
Delivery Devices for Therapeutic Substances
US 11,666,710
Granted 2023. Computed term ends 2041.
Vectors and Methods for Targeted Integration in Loci Comprising Constitutively Expressed Genes
US 10,745,717
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2035.
Detecting Cells of Interest in Large Image Datasets Using Artificial Intelligence
US 12,394,224
Granted 2025. Too new for citation comparison; protection runs to 2040.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Delivery Devices for Therapeutic Substances (US 11,666,710) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Delivery Devices for Therapeutic Substances | 2 in force | to Apr 2041 |
| Detecting Cells of Interest in Large Image Datasets Using Artificial Intelligence | 2 in force | to Feb 2041 |
| Vectors and Methods for Targeted Integration in Loci Comprising Constitutively Expressed Genes | 1 in force | to Nov 2035 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,745,717 | Vectors and Methods for Targeted Integration in Loci Comprising Constitutively Expressed Genes In force · High confidence | In force | High confidence | |
| US 12,394,224 | Detecting Cells of Interest in Large Image Datasets Using Artificial Intelligence In force · High confidence | In force | High confidence | |
| US 11,989,960 | Detecting Cells of Interest in Large Image Datasets Using Artificial Intelligence In force · High confidence | In force | High confidence | |
| US 11,666,710 | Delivery Devices for Therapeutic Substances In force · High confidence | In force | High confidence | |
| US 12,296,154 | Delivery Devices for Therapeutic Substances In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 27 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.